Inactive Instrument

Other languages Acasti Pharma Inc Toronto S.E.

Equities

APO

CA00430K4028

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12
Acasti Pharma Inc. Announces Poster Detailing Its GTX-104 STRIVE-ON Trial	Feb. 01
Acasti Pharma Inc. Approves Appointment of Robert J. Delaversano, as Principal Financial Officer and Principal Accounting Officer	Jan. 08
Acasti Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 13
Aker BioMarine Gains Krill Assets from Acasti Pharma in $3.1 Million Settlement Deal	23-10-24
Acasti Pharma Inc. Announces Board Changes	23-10-11
Acasti Pharma Insider Bought Shares Worth $1,249,934, According to a Recent SEC Filing	23-09-28
Acasti Pharma Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11
Top Midday Decliners	23-07-07
Acasti Pharma to Implement 1-for-6 Reverse Stock Split	23-07-07
Acasti Pharma Inc. Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol	23-07-05
Acasti Pharma Says it has Aligned With FDA Protocol for Phase 3 Trial of GTX-104; Receives New Drug Application Guidance	23-07-05
Acasti Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-23
Acasti Pharma Inc. Announces Scientific Advisory Board Appointments	23-06-22
Acasti Pharma Inc. Announces Executive Changes	23-05-11
Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Second Quarter 2025	23-05-08
Acasti Pharma Inc. to Proceed with Phase 3 Clinical Safety Study for GTX-104	23-04-05
Acasti Pharma Inc. Announces CEO Changes	23-04-05
Acasti Pharma Inc. Announces Resignation of Jean-Marie Canan from Board of Directors and Member of Audit Committee and Governance and Human Resources Committee	23-03-30
Acasti Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Acasti Pharma Inc Toronto S.E.

Equities

APO

CA00430K4028

Other languages

Filters